Abstract library

8 results for "Vivian".
#684 Clinical Characteristics and Survival of Neuroendocrine Tumors of Unknown Primary
Introduction: NETs of unknown primary account for 10-15% of NETs. There is limited published literature on this group of NETs.
Conference: 10th Annual ENETS Conference (2013)
Category: Surgical treatment
Presenting Author: Dr Raj Srirajaskanthan
#890 Prognostic Validity of the WHO 2010 TNM Staging and Grading Criteria for Pancreatic Neuroendocrine Tumors
Introduction: The TNM staging and grading system developed by the WHO was designed to help prognosticate patients.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: Mr Logan E Mills
#893 The Role of Primary Resection and Hepatic Resection in the Management of Metastatic Pancreatic Neuroendocrine Tumors with Irresectable Liver Metastases
Introduction: More than 40% of pancreatic neuroendocrine tumor (PNET) patients have liver metastases (LM) at diagnosis. Whilst it is agreed that, where possible, curative surgery offers the best outcomes, the role of debulking surgery in the context of irresectable LM remains unclear.
Conference: 11th Annual ENETS Conference (2014)
Category: Surgical treatment
Presenting Author: Mr Logan E Mills
Keywords: liver
#1209 Pancreatic Neuroendocrine Incidentalomas: When is Surgery in the Patient’s Best Interests?
Introduction: Small PNETs, many of which are diagnosed incidentally, pose a management dilemma. Whilst resection offers curative outcomes, the risks of surgery have led many to adopt surveillance strategies. 2cm is often used as a threshold for malignancy, but reports suggest that this value may not be valid.
Conference: 12th Annual ENETS Conference (2015)
Category: Surgical treatment
Presenting Author: Logan Mills
Keywords: PNET
#1239 Histological Classification of Pancreatic Neuroendocrine Tumours: Optimising the Ki67 System
Introduction: Pancreatic neuroendocrine tumours are graded using the Ki67 antigen in accordance with the WHO 2010 classification. Despite the system’s widespread use, a wide variety of tumour behaviours have been described leading to various proposed revisions.
Conference: 12th Annual ENETS Conference (2015)
Category: Pathology, grading, staging
Presenting Author: Logan Mills
Keywords: G3
#1839 Laparoscopic and Robotic Resection for Pancreatic Neuroendocrine Tumors (pNET): Less Is More?
Introduction: Laparoscopy is useful for the resection of pNET, but only a few studies in the Literature describes outcomes for a large series
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: DOCTOR Isacco Damoli
#2228 Prognostic Value of Lymph Node Status and Extent of Lymphadenectomy in Non Functioning Pancreatic Neuroendocrine Tumors: Outcome Analysis from 378 Consecutive Resections in a High-Volume Institution
Introduction: The optimal management of regional lymph nodes during resections of Pancreatic Neuroendocrine Tumors (pNETs) remains controversial. Conflicting data exist on predictors of LN metastases (LNM) and their impact on survival
Conference: 15th Annual ENETS conference (2018)
Category: Surgical treatment and Ablative Therapies
Presenting Author: doctor Anna Malpaga
Authors: Malpaga A, Miotto M, Elio G, Nessi C, ...
#2243 Somatostatin Analogs (SSAs) as Effective Treatment of Resectable, non Metastatic, non Functioning Pancreatic Neuroendocrine Tumors (NF-pNETs) in Patients Unfit for Surgery. A Case Series.
Introduction: SSAs are used to treat symptomatic functioning pNETs and to prolong progression free survival in metastatic, G1/G2, somatostatin receptor-positive pNETs. Pancreatic surgery is burdened with important morbidity and mortality, especially in patients with increased anaesthesiological risk.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Chiara Nessi
Authors: Nessi C, Paiella S, Miotto M, Viviani E, ...